On December 19th, the grand opening of the 2024 Cyzone 100 Future Unicorn Conference and Cyzone Annual Meeting, themed 'Crossing the Alps - Boundless Travelers', took place in Chengdu.  Novamab has been hornored on the 2024 Cyzone 100 Future Unicorn List for its outstanding performance and significant growth potential in biomedicine.  

The "Cyzone 100 Future Unicorns" focuses on high growth companies that have been established within 10 years, been valued between $100 million and $1 billion, andnot yet gone public. From a professional standpoint, it delves into the emerging business elite embodied by potential unicorns, uncovering the key factors driving the sustained nurturing, development, and swift expansion of China's unicorns and future unicorns. The successful listing of Novamab is not only a comprehensive reflection of the company's overall strength, as well as a strong indication of the capital market's high recognition of its future growth potential.

01   About the 2024 Cyzone 100 Future Unicorns

As one of the most authoritative investment research institutions in China, Cyzone's annual ranking serves as a benchmark for the Chinese capital market, offering authoritative evaluations and reference frameworks for the equity investment industry. Since 2009, Cyzone has continuously hosted the 'Cyzone 100 Future Unicorn Conference' selection for 15 years. The professional evaluation team, grounded in comprehensive analysis,Evaluated the performance of applicant enterprises based on capital value, growth rate, and development prospects, conducted data sorting, verification, research analysis, and interviews, ultimately selecting the '2024 Cyzone 100 Future Unicorns'.

02   About Novamab

Novamab Biopharmaceuticals Co., Ltd., founded in October 2017 in Shanghai International Medical Park, is a pioneering biopharmaceutical enterprise specializing in nanobody drug research and industrialization. It has established a complete research and development, CMC, and pilot production platform and system, and is currently the only company in China with full process development capabilities for nanobody drugs. Novamab has built a 500L Pichia pastoris nanobody GMP pilot production workshop, filling the industry gap in this field, which is extremely scarce and competitive. As of November 2024, Novamab has applied for more than 80 domestic and foreign invention patents and has been granted 31 patents. Novamab, a clinical-stage biopharmaceutical company, has a robust R&D pipeline that spans respiratory system, autoimmune disease, immuno-oncology, ophthalmology, and oncology. The company has achieved 4 clinical approvals, as detailed on its official website. The LQ036 and LQ043H products under development by Novamab have overturned the existing treatment methods for respiratory diseases, both representing the world's first inhaled nanobody drugs targeting the same condition. LQ036 has completed Phase I clinical trials in China and Australia, and is currently undergoing Phase II clinical trials in China. The Phase I clinical trials have shown promising results in terms of drug safety and biomarker efficacy. LQ043H, a project by Novamab, has successfully completed a Phase Ia clinical study in China, showcasing its excellent safety profile and drug tolerance. This study is part of the broader development plan for LQ043H, which aims to treat a wide range of moderate to severe asthma cases through inhalation. At the same time, the company fully leverages the advantages of nanobodies and actively lays out nanobody dual antibody and multi antibody platforms, including projects in the field of inflammatory bowel disease (IBD) and other autoimmune diseases that are rapidly advancing.